Search earnings tickers

ALNY

2025Q2BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2025-07-31 · Fiscal end 2025-06-30 · Features as of 2025-07-30

← Earnings history

Street

Consensus EPS0.15

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move2.5%

IV front—

P/C full—

P/C front—

Features as of2025-07-30

Run-up

Close—

Ret 5d+4.3%

Ret 10d+5.3%

Ret 20d+5.5%

Ret 30d+10.0%

Print

Actual EPS

0.32Beat

Estimated EPS0.15

Actual revenue

773.7M

Surprise %+113.3%

Beat / missBeat

Beat streak 43

Beat streak 83

Reaction

1-day stock reaction+12.1%

Implied vs actual

Implied 2.5%Actual 3.0%

Gap reaction+3.0%

Day result+15.4%

Next-day upYes

Realized / IV1.20×

Post tape

Post 5d+10.9%

Post 10d+12.9%

Post volume3.4M

Vol ×10d3.51×

Vol ×20d3.60×

Post range15.0%